ADV100 is a drug that has significant anti inflammatory and anti-fibrotic actions . It thus has therapeutic potential in reducing ocular surface disease secondary to tear deficiency induced by conditions such as ocular GVHD, Stevens Jonson syndrome and Sjogrens syndrome. Dry eye disease is seen with increased prevalence in patients with autoimmune diseases, which affect approximately 8% of the population, of whom 78% are women.
ADV300 is a novel AMES Negative HDAC6 inhibitor for the treatment of multiple cancers. Histone Deactylases (HDACs) can modulate a multitude of cellular processes and are a part of the regulation of cellular pathways involved in anti-tumor immune responses. Selective inhibition of HDAC6 slows tumor growth in various cancer models. Many prominent selective HDAC6 inhibitors are limited to pre-clinical research because they display mutagenic characteristics from the AMES test. ADV300 shows high potency against HDAC6, no mutagenicity and low cytotoxicity. Currently being evaluated in preclinical studies.
ADV200 is a panel of four tear fluid biomarkers (BM1-4) that serve as indicators of processes that contribute to pathophysiology of ocular surface diseases and will be used to initiate a therapy (e.g. ADV100) and follow response to the therapeutic intervention. The biomarker panel comprises molecules that are increased in ocular surface Inflammation (BM1), Epithelial barrier breakdown (BM2), Immunoproliferation (BM3) and Meibomian gland atrophy (BM4). The Biomarker panel will be marketed as a rapid result, in-office test.